13 research outputs found

    Phylogenetic tree obtained from 92 full length sequences.

    No full text
    <p>The evolutionary history was inferred using the Neighbor-Joining method with a bootstrap test (500 replicates); bootstrap values are shown next to the branches. Sequences from 60 acute cases (black dots) and 24 chronic cases (open dot) and 8 reference sequences (grey triangles) were analyzed.</p

    General flow chart of the study.

    No full text
    <p>Samples corresponding to notified AHB were classified according to both the values of HBc IgM and avidity index. Each biologically classified coherent case was thoroughly assessed for discrepancies with epidemiological and clinical information. When relevant information was not available physicians were interviewed on an individual basis.</p

    Distribution of HBV-VL (log<sub>10</sub> IU/mL) according to disease course.

    No full text
    <p>Black bars represent acute cases and gray bars anti-HBc IgM positive chronic cases and open bars anti-HBc IgM negative chronic cases.</p

    Drugs consumptions in the six months before acute HCV infection diagnosis in the 53 HIV-infected MSM with self-administered questionnaire, HEPAIG study, 2006–2007.

    No full text
    <p>Note. Data are no. (%) of patients. MDA, 3–4 methylene dioxy-amphetamine; GHB, gamma hydroxy butyric acid; <sup>a</sup>including anxiolytic, hypnotic or antidepressant; <sup>b</sup>several possible answers; <sup>c</sup>use at least 10 times during the six-month period</p

    Main characteristics of the 80 HIV-infected MSM at acute HCV infection diagnosis reported by physicians, medical questionnaire, HEPAIG study, 2006–2007.

    No full text
    <p>Note. Data are no. (%) of patients or median values (inter-quartile range); MSM, men who have sex with men; HAART, highly active antiretroviral treatment; STI, sexually transmitted infection; ALT, alanine aminotransferase; ULN, upper limit of normal; <sup>a</sup><50 copies/mL; <sup>b</sup>several possible answers; <sup>c</sup>anti-HCV (+) within one year after anti-HCV (-) or HCV RNA (+) within one year after both documented anti-HCV (-) and HCV RNA (-); <sup>d</sup>HCV RNA (+) either: i) within one year after two documented HCV RNA (-), or, ii) with symptoms of acute hepatitis and ALT level >10xULN within one year after regular controls of normal ALT (other causes excluded); <sup>e</sup>possible acute HCV infection following primary infection with confirmed viral clearance.</p
    corecore